E-ISSN: 2706-8927
P-ISSN: 2706-8919
www.allstudyjournal.com
IJAAS 2024; 6(5): 32-37
Received: 02-03-2024
Accepted: 07-04-2024

Puneet Mishra
Institute of Pharmaceutical Sciences & Research, Lucknow, Uttar Pradesh, India

Santosh Shukla
Institute of Pharmaceutical Sciences & Research, Lucknow, Uttar Pradesh, India

Corresponding Author:
Puneet Mishra
Institute of Pharmaceutical Sciences & Research, Lucknow, Uttar Pradesh, India

Advancements in nanotechnology for targeted drug delivery in postmenopausal osteoporosis

Puneet Mishra and Santosh Shukla

DOI: https://doi.org/10.33545/27068919.2024.v6.i5a.1166

Abstract
Recent advancements in drug delivery systems, particularly those utilizing nanotechnology, offer promising avenues for more effective treatment of osteoporosis, a silent and progressive disease prevalent among postmenopausal women. Nanoparticle-based drug delivery systems, including liposomes, polymeric nanoparticles, and micelles, enable targeted delivery of osteoporosis drugs to specific sites in the body, such as areas of bone loss. This targeted approach enhances drug concentration at the desired site while minimizing systemic exposure, thereby reducing adverse effects. Additionally, nanoparticles can be engineered for controlled drug release, prolonging its therapeutic effects. Surface modification of nanoparticles with targeting ligands, like bisphosphonates, further enhances their bone-targeting capabilities, ensuring efficient uptake by bone cells. Hydrogel-based drug delivery systems represent another innovative approach for osteoporosis treatment. Hydrogels, loaded with osteoporosis drugs, provide sustained release of the drug and can promote bone regeneration, enhancing therapeutic potential. Gene therapy, involving the delivery of genes encoding bone-stimulating factors, offers a promising avenue for the long-term management of osteoporosis by targeting underlying molecular mechanisms. Microneedle patches and 3D-printed implants provide minimally invasive and customizable drug delivery methods, enhancing patient convenience and compliance. Despite these advancements, challenges remain, including ensuring the safety and biocompatibility of nanomaterials, optimizing the targeting efficiency of nanoparticles, evaluating long-term effects and risks associated with gene therapy, and addressing the scalability and cost-effectiveness of advanced drug delivery systems. However, integrating nanotechnology into drug delivery systems has significantly advanced osteoporosis treatment, offering targeted and personalized therapies with minimized adverse effects and maximized therapeutic efficacy.

Keywords: Postmenopausal osteoporosis, targeted delivery, nanotechnology

1. Introductions

Osteoporosis, a silent and progressive disease characterized by decreased bone density and increased fracture risk, poses a significant health concern globally, particularly among postmenopausal women. The conventional treatments for osteoporosis often involve oral medications with systemic distribution, which can lead to various adverse effects [1]. However, recent advancements in drug delivery systems, particularly nanotechnology, offer promising avenues for more targeted and effective therapies. Nanoparticle-based drug delivery systems have emerged at the forefront of the treatment of osteoporosis. Nanoparticles, such as liposomes, polymeric nanoparticles, and micelles, possess unique properties that make them ideal for encapsulating osteoporosis drugs [2]. One of the key advantages of nanoparticles is their ability to facilitate targeted drug delivery, allowing drugs to reach specific sites in the body, such as areas of bone loss. This targeted approach enhances drug concentration at the desired site while minimizing systemic exposure, thereby reducing the adverse effects of conventional systemic therapies. Moreover, nanoparticles can be engineered to release the drug slowly over time, which prolongs its therapeutic effects [3]. This controlled release mechanism ensures a more sustained presence of the drug at the target site, maximizing its efficacy. Targeting bone tissue directly has become a focal point in recent research. Scientists are developing nanoparticles specifically designed to target bone tissue, delivering drugs directly to areas of bone loss [4].

Concentrating drug delivery at the site of action maximizes therapeutic efficacy while minimizing off-target effects. Surface modification of nanoparticles with targeting ligands, such as bisphosphonates, further enhances their bone-targeting capabilities, ensuring

efficient uptake by bone cells. These functionalized nanoparticles can selectively bind to receptors on bone cells, facilitating their internalization and improving drug delivery to the desired site [5]. Hydrogel-based drug delivery systems represent another innovative approach to the treatment of osteoporosis. Hydrogels, three-dimensional networks of hydrophilic polymers, can absorb and retain large amounts of water. Loaded with osteoporosis drugs, these hydrogels can be implanted at the site of bone loss [6]. One of the key advantages of hydrogels is their ability to provide sustained release of the drug, ensuring a continuous therapeutic effect over an extended period. Furthermore, hydrogels can promote bone regeneration, further enhancing their therapeutic potential. Gene therapy has also garnered significant attention in the treatment of osteoporosis [7]. This approach uses viral vectors or nanoparticles to deliver genes encoding bone-stimulating factors directly to bone cells. These genes can promote bone formation and inhibit bone resorption, potentially reversing bone loss.

Gene therapy offers a promising avenue for long-term management of osteoporosis by targeting the underlying molecular mechanisms. Microneedle patches have emerged as a minimally invasive drug delivery method for osteoporosis treatment [8]. These patches contain tiny needles coated with osteoporosis medication, which penetrate the skin and release the drug into the bloodstream. This approach offers improved patient convenience and compliance compared to traditional injections while ensuring precise drug delivery. Furthermore, 3D-printed implants loaded with osteoporosis drugs represent a cutting-edge approach in osteoporosis treatment [9]. These implants can be customized to fit the patient's anatomy and release the drug locally over an extended period. They provide a sustained therapeutic effect while reducing the frequency of drug administration, thereby enhancing patient comfort and compliance. The integration of nanotechnology into drug delivery systems has significantly advanced the field of osteoporosis treatment [10]. These innovative approaches offer targeted and personalized therapies, minimizing adverse effects while maximizing therapeutic efficacy. However, despite the promising potential of these advancements, several challenges remain. One of the primary challenges is ensuring the safety and biocompatibility of nanomaterials used in drug delivery systems. Additionally, optimizing the targeting efficiency of nanoparticles and enhancing their stability in biological environments requires further research [11]. Furthermore, gene therapy's long-term effects and potential risks must be thoroughly evaluated. Moreover, the scalability and cost-effectiveness of these advanced drug delivery systems need to be addressed to ensure their widespread adoption in clinical practice.

2. Nanoparticle-based drug delivery systems

Nanoparticles, such as liposomes, polymeric nanoparticles, and micelles, represent a promising approach to treating postmenopausal osteoporosis by encapsulating osteoporosis drugs and precisely delivering them to targeted sites within the body [12]. Due to their size and structure, these minute structures offer unique advantages in drug delivery. One of the key benefits of nanoparticles is their efficient encapsulation of osteoporosis drugs. This encapsulation shields the drugs from degradation and enables precise control over their release. In the context of postmenopausal osteoporosis, this means ensuring that the drugs are effectively delivered to the bone tissue, where they are most needed [13].

Furthermore, nanoparticles can be engineered to release the drug gradually over time. This sustained-release mechanism is particularly advantageous in osteoporosis treatment, ensuring a consistent and prolonged drug supply to the bone tissue. This prolonged exposure enhances the therapeutic effects while minimizing the potential for side effects [14]. Direct delivery of the drug to the bone tissue by nanoparticles minimizes systemic exposure, thereby reducing the risk of adverse effects commonly associated with conventional oral medications. This targeted delivery approach is crucial in postmenopausal osteoporosis, where the primary goal is to enhance bone density and reduce the risk of fractures while minimizing any side effects [15]. Overall, nanoparticles hold significant promise in treating postmenopausal osteoporosis by efficiently encapsulating osteoporosis drugs and delivering them precisely to the bone tissue while offering controlled release to optimize therapeutic effects and minimize side effects.

Nanoparticle-based drug delivery systems

Type	Nature	Techniques	Process	References
Liposomes	Spherical lipid bilayer vesicles	Encapsulation, surface modification	1. Lipid film hydration or solvent dispersion to encapsulate drugs. 2. Surface modification with ligands targeting bone tissue.	[16]
Polymeric nanoparticles	Synthetic polymer particles	Emulsion, nanoprecipitation, surface modification	1. Emulsification or nanoprecipitation to form polymer nanoparticles. 2. Surface modification to enhance bone targeting.	[17]
Micelles	Amphiphilic molecules forming core-shell structures	Self-assembly, surface modification	1. Self-assembly of amphiphilic molecules to form micelles. 2. Surface modification for improved bone targeting.	[18]
Dendrimers	Highly branched, tree-like structures	Encapsulation, surface modification	1. Synthesis of dendrimers with encapsulated drugs. 2. Surface functionalization for bone-targeting ligands.	[19]
Carbon Nanotubes	Cylindrical carbon structures	Functionalization, surface modification	1. Functionalization of carbon nanotubes with drug molecules. 2. Surface modification for bone targeting.	[20]
Quantum Dots	Semiconductor nanocrystals	Encapsulation, surface modification	1. Encapsulation of osteoporosis drugs within quantum dots. 2. Surface modification for targeted delivery.	[21]
Gold Nanoparticles	Metallic gold nanoparticles	Surface functionalization, conjugation	1. Functionalization of gold nanoparticles with osteoporosis drugs. 2. Conjugation with bone-targeting ligands.	[22]
Magnetic Nanoparticles	Iron oxide or other magnetic materials	Co-precipitation, surface modification	1. Co-precipitation to form magnetic nanoparticles loaded with drugs. 2. Surface modification for bone targeting.	[23]

Silica Nanoparticles	Silicon dioxide nanoparticles	Sol-gel synthesis, surface modification	1. Synthesis of silica nanoparticles using sol-gel techniques. 2. Surface functionalization for bone targeting.	[24]
Protein Nanoparticles	Protein-based nanocarriers	Self-assembly, surface modification	1. Self-assembly of protein nanoparticles loaded with drugs. 2. Surface modification for targeted delivery.	[25]

2.1 Targeting bone tissue

Researchers are currently pioneering the development of nanoparticles with a specific affinity for bone tissue, aiming to deliver drugs directly to sites where bone loss occurs. This innovative approach allows for a significant increase in drug concentration precisely at the target site while minimizing exposure to the rest of the body, thereby reducing the risk of adverse effects [26]. The concept behind this strategy is to utilize nanoparticles that naturally tend to accumulate in bone tissue. By leveraging the unique properties of these nanoparticles, drugs can be effectively delivered directly to the areas affected by osteoporosis. This targeted delivery mechanism ensures that the drug acts exactly where it's needed most, maximizing its therapeutic efficacy [27].

One of the key advantages of this approach is the ability to enhance drug concentration at the site of bone loss while minimizing systemic exposure. Traditional systemic administration of osteoporosis drugs often leads to widespread distribution throughout the body, which can increase the likelihood of adverse effects [28]. Researchers can circumvent this issue by directly targeting bone tissue, delivering the drug precisely where it's required while minimizing exposure to healthy tissues. Moreover, this targeted delivery approach can potentially improve patient outcomes by reducing the required dosage of the drug. When drugs are delivered directly to the site of bone loss, a lower dose is often sufficient to achieve the desired therapeutic effect. This decreases the risk of adverse effects and enhances patient compliance and overall treatment efficacy [29].

2.2 Surface-modified nanoparticles:

Modifying nanoparticles with targeting ligands represents a promising strategy for enhancing drug delivery to bone tissue, particularly in postmenopausal osteoporosis. By attaching specific ligands to the surface of nanoparticles, researchers aim to increase their affinity for receptors on bone cells, thereby improving their uptake by bone tissue. One example of this approach involves functionalizing nanoparticles with bisphosphonates, which are known to have a high affinity for bone mineral [30]. When these nanoparticles are modified with bisphosphonates, they gain enhanced bone-targeting capabilities. Bisphosphonates attract calcium ions in bone tissue, allowing the nanoparticles to bind specifically to the bone surface. Once bound to the bone surface, these nanoparticles can deliver drugs directly to the osteoclasts and osteoblasts, the cells responsible for bone remodeling [31]. This targeted delivery mechanism ensures that the drugs are delivered precisely to the site of bone loss, maximizing their therapeutic efficacy while minimizing systemic exposure. Moreover, surface modification with targeting ligands such as bisphosphonates improves the uptake of nanoparticles by bone tissue and enhances their retention within the bone matrix. This prolonged residence time increases the duration of drug action at the target site, further enhancing the therapeutic effects [32]. Surface-modified nanoparticles specifically target bone tissue, offer a promising approach for treating postmenopausal osteoporosis. This targeted delivery strategy minimizes off-target effects and reduces the required dosage of the drug, thereby minimizing adverse effects. Enhancing drug uptake and retention within bone tissue improves treatment efficacy and patient outcomes [33].

2.3 Hydrogel-based drug delivery

Hydrogels, three-dimensional networks of hydrophilic polymers, offer a promising solution for treating postmenopausal osteoporosis. These unique materials can absorb and retain large amounts of water, making them ideal candidates for delivering osteoporosis drugs directly to the site of bone loss. One of the key advantages of hydrogels is their capacity to be loaded with osteoporosis drugs and implanted precisely at the affected area of bone loss [34]. This targeted delivery approach ensures that the drugs are delivered directly to the site where they are needed most, minimizing systemic exposure and reducing the risk of side effects. Moreover, hydrogels provide a sustained release of the drug over an extended period. As the hydrogel slowly degrades, it releases the encapsulated drug gradually, maintaining therapeutic levels within the bone tissue for longer durations [35]. This sustained release mechanism is particularly beneficial in osteoporosis treatment, as it ensures a continuous supply of the drug to promote bone remodeling and repair.

Additionally, hydrogels have been shown to promote bone regeneration. By creating a favorable microenvironment for bone cells, hydrogels can stimulate the growth of new bone tissue, ultimately enhancing bone density and strength. This dual functionality of hydrogels in delivering drugs and promoting bone regeneration makes them a promising option for treating postmenopausal osteoporosis [36]. Furthermore, hydrogels' biocompatibility makes them well-suited for use in clinical settings. They are non-toxic and can be easily integrated into the body without causing adverse reactions. This ensures patient safety and enhances the feasibility of using hydrogels as a therapeutic option for postmenopausal osteoporosis [37].

2.4 Gene therapy

Gene therapy holds considerable promise in the realm of treating postmenopausal osteoporosis. This innovative approach involves delivering genes that encode bone-stimulating factors directly to bone cells, facilitated by viral vectors or nanoparticles. The objective is to trigger a biological response within the bone tissue that enhances bone formation and inhibits bone resorption, potentially reversing the progression of bone loss [38]. In postmenopausal osteoporosis, the imbalance between bone formation and resorption often leads to a decrease in bone density and an increased risk of fractures. Gene therapy offers a targeted solution to this problem by addressing the underlying mechanisms that contribute to bone loss. Viral vectors or nanoparticles are used as carriers to transport the therapeutic genes into bone cells. These carriers are designed to protect the genes and facilitate their delivery to the target cells. Once inside the bone cells, the therapeutic genes can exert their effects [39].

One of the key advantages of gene therapy is its ability to promote bone formation directly. Genes encoding bone-stimulating factors, such as bone morphogenetic proteins (BMPs) or growth factors like BMP-2 and BMP-7, can be delivered to stimulate osteoblasts, the cells responsible for bone formation. This promotes the synthesis of new bone tissue, increasing bone density and strength. Additionally, gene therapy can inhibit bone resorption by targeting osteoclasts, the cells responsible for breaking down bone tissue [40]. Genes encoding inhibitors of osteoclast activity, such as osteoprotegerin (OPG), can be delivered to reduce bone resorption, thereby preserving existing bone mass. By combining both strategies—promoting bone formation and inhibiting bone resorption—gene therapy offers a comprehensive approach to reversing bone loss in postmenopausal osteoporosis. However, there are challenges associated with gene therapy, including ensuring the safety and efficacy of gene delivery, controlling the duration and intensity of gene expression, and addressing potential immune responses to the viral vectors [41]. Additionally, further research is needed to optimize gene therapy techniques and determine the long-term effects of treatment. Despite these challenges, gene therapy holds great potential as a novel and targeted approach for treating postmenopausal osteoporosis. With ongoing research and development, gene therapy may offer new avenues for effectively managing this debilitating condition and improving the quality of life for affected individuals [42].

2.5 Microneedle patches

Microneedle patches are emerging as a promising minimally invasive approach for delivering osteoporosis drugs. These patches consist of tiny needles coated with osteoporosis medication, designed to penetrate the skin and deliver the drug directly into the bloodstream. This innovative method offers several advantages over traditional injections, including improved patient convenience and compliance. Microneedle patches provide a simple and painless alternative to conventional injections [43]. They involve gentle application onto the skin rather than the use of hypodermic needles, which makes them particularly appealing for patients who may have needle phobia or experience discomfort with injections. Moreover, the microneedles are designed to be very small, typically less than a millimeter in length, which minimizes pain and discomfort during application. They are also engineered to dissolve upon insertion into the skin, releasing the encapsulated drug into the bloodstream gradually [44].

This controlled release mechanism ensures a consistent and sustained delivery of the medication over time, which can lead to more stable blood levels of the drug than traditional injections. This stability in drug levels may contribute to better therapeutic outcomes in managing postmenopausal osteoporosis. Furthermore, microneedle patches offer improved patient compliance due to their ease of use and portability. Patients can self-administer the patches at home without needing healthcare professionals, reducing the burden of frequent clinic visits for injections [45]. Additionally, using microneedle patches eliminates the need for needle disposal, making them a more environmentally friendly option. This feature aligns with the growing trend toward sustainable healthcare practices. Overall, microneedle patches represent a convenient, painless, and effective method for delivering osteoporosis drugs to postmenopausal women. Their simplicity of use, controlled drug release, and improved patient compliance make them a promising alternative to traditional injection methods in the management of osteoporosis. Continued research and development in this area hold potential for further enhancing the efficacy and accessibility of microneedle patch technology in osteoporosis treatment [46].

2.6 3D-printed implants

3D-printed implants loaded with osteoporosis drugs represent a cutting-edge approach to treating postmenopausal osteoporosis. These implants are customized to fit each patient's unique anatomy, offering a personalized treatment solution. By incorporating osteoporosis medication into the implant material, they can release the drug locally over an extended period directly to the affected bone tissue [47]. One of the major advantages of 3D-printed implants is their ability to match the patient's bone structure precisely, ensuring optimal fit and integration. This customization enhances the effectiveness of drug delivery by maximizing contact between the implant and the bone tissue, leading to improved therapeutic outcomes. Additionally, the ability to load the implants with osteoporosis drugs allows for a sustained therapeutic effect [48]. As the implant gradually releases the medication into the surrounding bone, it maintains therapeutic levels over an extended period, reducing the frequency of drug administration. This sustained release mechanism ensures continuous treatment and minimizes drug level fluctuations, which can improve patient outcomes. Furthermore, 3D-printed implants offer advantages in terms of patient comfort and convenience [49]. Unlike traditional oral medications or injections, which require regular dosing, these implants provide a long-lasting treatment option with minimal intervention. Patients do not need to remember to take daily medications or undergo frequent injections, which can improve compliance and quality of life. Moreover, the localized drug delivery provided by 3D-printed implants minimizes systemic exposure to the medication, reducing the risk of side effects associated with conventional treatments [50]. These implants maximize therapeutic efficacy by targeting the drug specifically to the affected bone tissue while minimizing adverse effects on other organs or tissues.

3. Conclusion

In conclusion, the integration of nanotechnology into drug delivery for postmenopausal osteoporosis offers a wide range of promising strategies to enhance treatment efficacy and patient well-being. From nanoparticle-based systems to gene therapy and 3D-printed implants, these approaches provide tailored solutions to combat the challenges of osteoporosis. Nanoparticle-based drug delivery, utilizing liposomes, polymeric nanoparticles, and micelles, allows targeted delivery of osteoporosis medications, minimizing side effects while maximizing therapeutic effects. Surface-modified nanoparticles further improve bone targeting, ensuring efficient uptake by bone tissue. Hydrogel-based drug delivery provides sustained drug release and promotes bone regeneration, offering a dual benefit in osteoporosis treatment. Gene therapy potentially reverses bone loss by delivering bone-stimulating factors directly to bone cells, and microneedle patches offer a convenient and minimally invasive drug delivery method. 3D-printed implants,

tailored to individual anatomy, offer localized drug delivery over time, enhancing patient compliance. In sum, these innovative drug delivery approaches can potentially transform osteoporosis treatment, providing safer, more effective, and patient-friendly options. Further research and development are vital to optimizing these strategies for clinical use and enhancing the lives of postmenopausal osteoporosis patients.

4. References

1. Wei D, Jung J, Yang H, Stout DA, Yang L. Nanotechnology treatment options for osteoporosis and its corresponding consequences. Current osteoporosis reports. 2016;14:239-47.
2. Luo Y, Liu H, Chen M, Zhang Y, Zheng W, Wu L, *et al*. Immunomodulatory Nanomedicine for Osteoporosis: Current Practices and Emerging Prospects. Acta Biomaterialia; c2024.
3. Crișan S, Pop AL, Lacatusu I, Badea N, Mustaciosu C, Radu M, *et al*. Safety of Innovative Nanotechnology Oral Formulations Loaded with Bioactive Menopause Molecules: Influence of Genotoxicity and Biochemical Parameters on a Menopausal Rat Model. Nutrients. 2023;15(23):4951.
4. Luo Y, Liu H, Chen M, Zhang Y, Zheng W, Wu L, *et al*. Immunomodulatory Nanomedicine for Osteoporosis: Current Practices and Emerging Prospects. Acta Biomaterialia; c2024.
5. Chang Z, Chen D, Peng J, Liu R, Li B, Kang J, *et al*. Bone-Targeted Supramolecular Nanoagonist Assembled by Accurate Ratiometric Herbal-Derived Therapeutics for Osteoporosis Reversal. Nano Letters; c2024.
6. Liao J, Lu L, Chu X, Xiong Y, Zhou W, Cao F, *et al*. Cell membrane coated nanoparticles: A cutting-edge drug delivery system for anti-osteoporosis therapy. Nanoscale; c2024.
7. Pant A, Singh J, Barnwal RP, Singh G, Singh B. Theranostic approach for the management of osteoporosis. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2023, 40(3).
8. Rahmani D, Faal B, Zali H, Tackallou SH, Niknam Z. The beneficial effects of simultaneous supplementation of Lactobacillus reuteri and calcium fluoride nanoparticles on ovariectomy-induced osteoporosis. BMC Complementary Medicine and Therapies. 2023;23(1):340.
9. Ray SS, Brits J, Deware K. Osteoporosis and Its Nanotechnology-Based Advanced Treatment—An Overview. Journal of Biomedical Nanotechnology. 2021;17(5):809-21.
10. Hussain Z. Nanotechnology guided newer intervention for treatment of osteoporosis: efficient bone regeneration by up-regulation of proliferation, differentiation and mineralization of osteoblasts. International Journal of Polymeric Materials and Polymeric Biomaterials. 2021;70(1):1-3.
11. Crișan S, Pop AL, Lacatusu I, Badea N, Mustaciosu C, Radu M, *et al*. Safety of Innovative Nanotechnology Oral Formulations Loaded with Bioactive Menopause Molecules: Influence of Genotoxicity and Biochemical Parameters on a Menopausal Rat Model. Nutrients. 2023;15(23):4951.
12. Salamanna F, Gambardella A, Contartese D, Visani A, Fini M. Nano-based biomaterials as drug delivery systems against osteoporosis: a systematic review of preclinical and clinical evidence. Nanomaterials. 2021;11(2):530.
13. Wei D, Jung J, Yang H, Stout DA, Yang L. Nanotechnology treatment options for osteoporosis and its corresponding consequences. Current osteoporosis reports. 2016;14:239-47.
14. Barry M, Pearce H, Cross L, Tatullo M, Gaharwar AK. Advances in Nanotechnology for the Treatment of Osteoporosis. Current osteoporosis reports. 2016;14:87-94.
15. Shukla A, Dasgupta N, Ranjan S, Singh S, Chidambram R. Nanotechnology towards prevention of anaemia and osteoporosis: from concept to market. Biotechnology & Biotechnological Equipment. 2017;31(5):863-79.
16. Nirwan N, Nikita, Sultana Y, Vohora D. Liposomes as multifaceted delivery system in the treatment of osteoporosis. Expert Opinion on Drug Delivery. 2021;18(6):761-75.
17. Kaur M, Nagpal M, Aggarwal G. Nanotechnology for Targeted Drug Delivery to Treat Osteoporosis. Current Drug Targets. 2023;24(1):2-12.
18. Varshosaz J, Ziaei V, Minaiyan M, Jahanian-Najafabadi A, Sayed-Tabatabaei L. Enhanced solubility, oral bioavailability and anti-osteoporotic effects of raloxifene HCl in ovariectomized rats by Igepal CO-890 nanomicelles. Pharmaceutical Development and Technology. 2019;24(2):133-44.
19. Kaur M, Nagpal M, Aggarwal G. Nanotechnology for Targeted Drug Delivery to Treat Osteoporosis. Current Drug Targets. 2023;24(1):2-12.
20. de Carvalho JO, de Carvalho Oliveira F, Freitas SA, Soares LM, de Cássia Barros Lima R, de Sousa Gonçalves L, *et al*. Carbon nanomaterials for treating osteoporotic vertebral fractures. Current Osteoporosis Reports. 2018;16:626-34.
21. Ray SS, Brits J, Deware K. Osteoporosis and Its Nanotechnology-Based Advanced Treatment—An Overview. Journal of Biomedical Nanotechnology. 2021;17(5):809-21.
22. Cheng X, Li D, Cui R. Introducing a novel therapeutic supplement for osteoporosis: Remedial, cytotoxicity and antioxidant effects of plant extract green-formulated gold nanoparticles. Journal of Engineering Research; c2023.
23. Barry M, Pearce H, Cross L, Tatullo M, Gaharwar AK. Advances in Nanotechnology for the Treatment of Osteoporosis. Current osteoporosis reports. 2016;14:87-94.
24. Ha SW, Viggeswarapu M, Habib MM, Beck Jr GR. Bioactive effects of silica nanoparticles on bone cells are size, surface, and composition dependent. Acta biomaterialia. 2018;82:184-96.
25. Luk KH, Chan CH, Liu ZW, Jiao CW, Yang XB, Dong XL, *et al*. Selenium nanoparticles functionalized by mushroom polysaccharide-protein complex: A novel nano-mineral for managing postmenopausal osteoporosis. Journal of Functional Foods. 2023;110:105832.
26. Barry M, Pearce H, Cross L, Tatullo M, Gaharwar AK. Advances in Nanotechnology for the Treatment of

Osteoporosis. Current osteoporosis reports. 2016;14:87-94.
27. Kaur M, Nagpal M, Aggarwal G. Nanotechnology for Targeted Drug Delivery to Treat Osteoporosis. Current Drug Targets. 2023;24(1):2-12.
28. Zhou X, Cornel EJ, He S, Du J. Recent advances in bone-targeting nanoparticles for biomedical applications. Materials Chemistry Frontiers. 2021;5(18):6735-59.
29. Balaji V, Mahalingam G. Nanoparticles-based drug delivery to cure osteo degeneration by improving tissue regeneration. In Advances in Nanotechnology-Based Drug Delivery Systems 2022, p. 449-470. Elsevier.
30. Li J, Chen X, Lu L, Yu X. The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. Cytokine & growth factor reviews. 2020;52:88-98.
31. Eskandarynasab M, Etemad-Moghadam S, Alaeddini M, Doustimotlagh AH, Nazeri A, Dehpour AR, *et al*. Novel osteoprotective nanocochleate formulation: a dual combination therapy-codelivery system against glucocorticoid induced osteoporosis. Nanomedicine: Nanotechnology, Biology and Medicine. 2020;29:102273.
32. Botelho MA, Queiroz DB, Barros G, Guerreiro S, Fechine P, Umbelino S, *et al*. Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study. Clinics. 2014;69:75-82.
33. Thurner GC, Haybaeck J, Debbage P. Targeting drug delivery in the elderly: are nanoparticles an option for treating osteoporosis?. International Journal of Molecular Sciences. 2021;22(16):8932.
34. Shar A, Aboutalebianaraki N, Misiti K, Sip YY, Zhai L, Razavi M. A novel ultrasound-mediated nanodroplet-based gene delivery system for osteoporosis treatment. Nanomedicine: Nanotechnology, Biology and Medicine. 2022;41:102530.
35. Chang Z, Chen D, Peng J, Liu R, Li B, Kang J, Guo L, *et al*. Bone-Targeted Supramolecular Nanoagonist Assembled by Accurate Ratiometric Herbal-Derived Therapeutics for Osteoporosis Reversal. Nano Letters; c2024.
36. Balaji V, Mahalingam G. Department of Biotechnology, School of BioSciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India. Advances in Nanotechnology-Based Drug Delivery Systems. 2022;6:449.
37. Yang X, Chen S, Liu X, Yu M, Liu X. Drug delivery based on nanotechnology for target bone disease. Current Drug Delivery. 2019;16(9):782-792.
38. Baltzer AW, Whalen JD, Wooley P, Latterman C, Truchan LM, Robbins PD, *et al*. Gene therapy for osteoporosis: evaluation in a murine ovariectomy model. Gene therapy. 2001;8(23):1770-1776.
39. Yang K, Miron RJ, Bian Z, Zhang YF. A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice. Bone. 2018;114:40-49.
40. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. The Journal of steroid biochemistry and molecular biology. 2014;142:155-170.
41. Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, *et al*. Postmenopausal osteoporosis. Nature reviews Disease primers. 2016;2(1):1-6.
42. Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D. Treatment needs and current options for postmenopausal osteoporosis. Expert opinion on pharmacotherapy. 2016;17(8):1141-52.
43. Daddona PE, Matriano JA, Mandema J, Maa YF. Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharmaceutical research. 2011;28:159-165.
44. Sim J, Kang G, Yang H, Jang M, Kim Y, Ahn H, *et al*. Development of clinical weekly-dose teriparatide acetate encapsulated dissolving microneedle patch for efficient treatment of osteoporosis. Polymers. 2022;14(19):4027.
45. Li Y, Ju XJ, Fu H, Zhou CH, Gao Y, Wang J, *et al*. Composite separable microneedles for transdermal delivery and controlled release of salmon calcitonin for osteoporosis therapy. ACS Applied Materials & Interfaces. 2022;15(1):638-650.
46. Katsumi H, Tanaka Y, Hitomi K, Liu S, Quan YS, Kamiyama F, *et al*. Efficient transdermal delivery of alendronate, a nitrogen-containing bisphosphonate, using tip-loaded self-dissolving microneedle arrays for the treatment of osteoporosis. Pharmaceutics. 2017;9(3):29.
47. Bai H, Cui Y, Wang C, Wang Z, Luo W, Liu Y, *et al*. 3D printed porous biomimetic composition sustained release zoledronate to promote osteointegration of osteoporotic defects. Materials & Design. 2020;189:108513.
48. Kwon BJ, Seon GM, Lee MH, Koo MA, Kim MS, Kim D, *et al*. Locally delivered ethyl-2, 5-dihydroxybenzoate using 3D printed bone implant for promotion of bone regeneration in a osteoporotic animal model.
49. Wang W, Xiong Y, Zhao R, Li X, Jia W. A novel hierarchical biofunctionalized 3D-printed porous Ti6Al4V scaffold with enhanced osteoporotic osseointegration through osteoimmunomodulation. Journal of Nanobiotechnology. 2022;20(1):68.
50. Li Z, Zhao Y, Wang Z, Ren M, Wang X, Liu H, *et al*. Engineering Multifunctional Hydrogel-Integrated 3D Printed Bioactive Prosthetic Interfaces for Osteoporotic Osseointegration. Advanced Healthcare Materials. 2022;11(11):2102535.